Wednesday, December 19, 2018
Zimmer Biomet downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Robert Marcus downgraded Zimmer Biomet Holdings to Neutral and lowered his price target for the shares to $118 from $140. The analyst believes the company’s long-term outlook is intact but he sees limited near-term upside.
https://thefly.com/landingPageNews.php?id=2838995
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.